Lupin enters into strategic licensing agreement with MonoSol Rx

06 Oct 2016 Evaluate

Lupin Pharmaceutical Inc, the US subsidiary of pharma major Lupin (collectively Lupin) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic licensing agreement wherein Lupin would develop multiple pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology.  MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film. MonoSol Rx is a global leader in filmbased drug delivery applications with two FDA-approved products and a robust pipeline of pharmaceuticals in development.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2115.75 26.10 (1.25%)
17-Dec-2025 12:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1278.30
Cipla 1493.10
Zydus Lifesciences 919.75
Lupin 2115.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×